Jeffrey Hessekiel Sells 50,000 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 50,000 shares of Exelixis stock in a transaction on Friday, November 1st. The stock was sold at an average price of $34.13, for a total value of $1,706,500.00. Following the sale, the executive vice president now owns 530,325 shares in the company, valued at $18,099,992.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jeffrey Hessekiel also recently made the following trade(s):

• On Monday, October 28th, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The stock was sold at an average price of $28.39, for a total value of $709,750.00.
• On Monday, September 23rd, Jeffrey Hessekiel sold 25,000 shares of Exelixis stock. The stock was sold at an average price of $26.38, for a total value of $659,500.00.
• On Monday, August 26th, Jeffrey Hessekiel sold 20,000 shares of Exelixis stock. The stock was sold at an average price of $25.79, for a total value of $515,800.00.

Exelixis Trading Up 1.4 %

Shares of NASDAQ:EXEL traded up $0.48 during trading on Tuesday, reaching $34.77. 2,754,724 shares of the company traded hands, compared to its average volume of 2,076,046. The firm has a market capitalization of $9.93 billion, a price-to-earnings ratio of 22.08, a P/E/G ratio of 0.92 and a beta of 0.51. Exelixis, Inc. has a 52-week low of $19.20 and a 52-week high of $35.15. The business’s fifty day moving average is $27.30 and its 200-day moving average is $24.39.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to the consensus estimate of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. On average, sell-side analysts predict that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Exelixis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Farallon Capital Management LLC raised its holdings in Exelixis by 1.6% in the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock worth $608,993,000 after purchasing an additional 424,000 shares in the last quarter. Renaissance Technologies LLC boosted its position in Exelixis by 0.4% in the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company’s stock worth $340,714,000 after purchasing an additional 61,350 shares during the last quarter. LSV Asset Management boosted its position in Exelixis by 107.7% in the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after purchasing an additional 2,989,021 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company’s stock worth $115,434,000 after purchasing an additional 349,837 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Exelixis by 12.7% in the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after buying an additional 370,199 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analysts Set New Price Targets

EXEL has been the topic of a number of recent analyst reports. Oppenheimer reiterated an “outperform” rating and set a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Stifel Nicolaus boosted their price objective on Exelixis from $26.00 to $30.00 and gave the company a “hold” rating in a research note on Wednesday, October 16th. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. TD Cowen boosted their price objective on Exelixis from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Guggenheim boosted their price objective on Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $31.44.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.